Short Interest in OpGen, Inc. (OPGN) Increases By 24.3%
OpGen, Inc. (NASDAQ:OPGN) was the target of a large growth in short interest in the month of July. As of July 31st, there was short interest totalling 2,692,022 shares, a growth of 24.3% from the July 14th total of 2,165,093 shares. Based on an average daily volume of 4,261,875 shares, the days-to-cover ratio is presently 0.6 days. Approximately 8.7% of the shares of the company are short sold.
In related news, CFO Timothy C. Dec acquired 65,000 shares of OpGen stock in a transaction that occurred on Tuesday, July 18th. The stock was acquired at an average price of $0.40 per share, for a total transaction of $26,000.00. Following the transaction, the chief financial officer now directly owns 118,966 shares of the company’s stock, valued at approximately $47,586.40. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Chairman Jven Capital, Llc acquired 1,875,000 shares of OpGen stock in a transaction that occurred on Tuesday, July 18th. The shares were bought at an average price of $0.40 per share, with a total value of $750,000.00. The disclosure for this purchase can be found here. Insiders own 53.27% of the company’s stock.
A hedge fund recently raised its stake in OpGen stock. Vanguard Group Inc. boosted its position in shares of OpGen, Inc. (NASDAQ:OPGN) by 1.6% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 342,860 shares of the medical research company’s stock after buying an additional 5,500 shares during the period. Vanguard Group Inc. owned 1.25% of OpGen worth $219,000 as of its most recent filing with the SEC. 9.25% of the stock is currently owned by institutional investors and hedge funds.
OpGen (NASDAQ OPGN) opened at 0.2722 on Friday. OpGen has a 12 month low of $0.26 and a 12 month high of $3.10. The firm’s 50-day moving average price is $0.43 and its 200-day moving average price is $0.83. The firm’s market cap is $14.03 million.
A number of research firms recently issued reports on OPGN. HC Wainwright set a $1.00 price objective on OpGen and gave the company a “buy” rating in a research report on Wednesday. Zacks Investment Research upgraded OpGen from a “sell” rating to a “hold” rating in a research report on Wednesday, June 28th. Finally, Dawson James reiterated a “buy” rating on shares of OpGen in a research report on Monday, June 19th.
OpGen, Inc (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms.
Receive News & Ratings for OpGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.